OncoSec Medical Incorporated (ONCS)
| Market Cap | 154.16M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -42.79M |
| Shares Out | 28.68M |
| EPS (ttm) | -1.71 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $4.02 |
| Previous Close | $4.09 |
| Change ($) | -0.07 |
| Change (%) | -1.71% |
| Day's Open | 4.15 |
| Day's Range | 4.02 - 4.31 |
| Day's Volume | 204,178 |
| 52-Week Range | 1.51 - 8.16 |
PENNINGTON, N.J. and SAN DIEGO, April 15, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...
PENNINGTON, N.J. and SAN DIEGO, April 14, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral imm...
PENNINGTON, N.J. and SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a biotechnology company focused on cytokine-based intratumoral can...
PENNINGTON, N.J. and SAN DIEGO, Feb. 18, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced the appointment of Bridget O'Keeffe, Ph.D., a biotec...
PENNINGTON, N.J. and SAN DIEGO, Jan. 27, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) today announced that it has dosed several subjects in its Phase 1 clinical trial of CORVax12, th...
PENNINGTON, N.J. and SAN DIEGO, Jan. 20, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company focused on designing, developing...
PENNINGTON, N.J. and SAN DIEGO, Nov. 24, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a late-stage biotechnology company developing intra-tumoral cancer ...
OncoSec has had very promising results in metastatic melanoma. It has also expanded its program in triple-negative breast cancer to now treat first-line patients.
PENNINGTON, N.J. and SAN DIEGO, Nov. 9, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced new positive interim data from its KEYNOTE-695 regist...
PENNINGTON, N.J. and SAN DIEGO, Oct. 12, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a company developing late- stage intra-tumoral cancer immunotherapi...
PENNINGTON, N.J. and SAN DIEGO, Aug.
SAN DIEGO and PENNINGTON, N.J., Aug. 16, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that in connection with its previously announced of...
SAN DIEGO and PENNINGTON, N.J., Aug. 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS) (the "Company" or "OncoSec") today announced that it intends to offer and sell shares of its com...
PENNINGTON, N.J. and SAN DIEGO, May 14, 2020 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ: ONCS), a company developing late-stage intratumoral cancer immunotherapies, announced today that its pa...
Markets soar on US-China trade talk optimism.
OncoSec Medical announced that it has licensed a CAR-T product from Dana-Farber Cancer Institute, specifically from The Marasco Laboratory.
OncoSec Medical (ONCS) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
About ONCS
OncoSec Medical Incorporated, a biotechnology company, focuses on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer. The company's lead product candidate is ImmunoPulse IL-12 that uses electroporation device to deliver a DNA-encoded interleukin-12 (IL-12) for reversing the immunosuppressive microenvironment in the treated tumor. It is also developing ImmunoPulse IL-12 with KEYTRUDA in patients with advanced melanoma that is in Phase IIb clinical trials (KEYNOTE-695) and adva... [Read more...]
| Industry Biotechnology | Founded 2008 |
| CEO Daniel O'Connor | Employees 42 |
| Stock Exchange NASDAQ | Ticker Symbol ONCS |
Analyst Forecasts
According to 3 analysts, the average rating for ONCS stock is "Strong Buy." The 12-month stock price forecast is 9.75, which is an increase of 142.54% from the latest price.